Mark Robert Openshaw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mark Robert Openshaw has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- David James Pinato
Department of Surgery & Cancer Imperial College London, Hammersmith Hospital London UK
70 shared publications - Alessio Cortellini
Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
69 shared publications - Alexandra Emilia Schlaak
13Department of Internal Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
69 shared publications - Anna-Mary Young
12Department of Medical Oncology, St Georges University Hospitals, NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, London, United Kingdom
69 shared publications - Antonio D'Alessio
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK
69 shared publications - Bertram Bengsch
Department of Internal Medicine, Medical Center - University of Freiburg, Freiburg, Germany
69 shared publications
Latest Publications
- 20 September 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-7
Racial and Ethnic Disparities in Treatment Outcomes of Patients with Colorectal Cancer (CRC) in the UK: A Systematic Review
- 20 September 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-7
Racial and Ethnic Disparities in Treatment Outcomes of Patients with Colorectal Cancer (CRC) in the UK: A Systematic Review
- Open Access
- 10 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1642552
Anti-oxidative stress therapies prevent severe chemotherapy-induced peripheral neuropathy in colorectal cancer patients treated with oxaliplatin: a systematic review and meta-analysis
Background and purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side-effect of many commonly used cancer drugs, affecting up to 90% of patients treated with oxaliplatin. This systematic review and meta-analysis analysed randomised controlled trials (RCTs) to determine if any pharmacological agents or traditional medicines can prevent oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer (CRC) patients.Materials and methods: We searched PubMed, EMBASE and Web of Science for RCTs published before March 2025 that included patients with CRC who received oxaliplatin-based chemotherapy and had peripheral neuropathy quantified using Common Toxicity Criteria for Adverse Events (CTCAE). Meta-analysis was performed for agents tested in three or more RCTs with a minimum combined sample size of 100 patients.Results: 20 studies were included in the systematic review with a median sample size of 61 (range 14-2450). Meta-analysis was conducted for two treatments: first, agents with anti-oxidative stress properties and second, Ca2+/Mg2+ infusions. Anti-oxidative stress treatments were associated with a significant reduction of grade ≥2 OIPN at the end of treatment (OR:0.04, 95%CI:0.01-0.12; p2+/Mg2+ infusions. 35% of studies had potential high risk of bias and 45% of studies showed low risk of bias.Conclusions: Whilst the existing published RCTs included small numbers of patients, the meta-analysis indicates that anti-oxidative stress therapies can prevent severe OIPN developing at the end of treatment in CRC patients. A large, randomised, placebo-controlled trial assessing OIPN using CTCAE grades and patient-reported outcomes is warranted to confirm these findings.
- 10 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1642552
Open AccessAnti-oxidative stress therapies prevent severe chemotherapy-induced peripheral neuropathy in colorectal cancer patients treated with oxaliplatin: a systematic review and meta-analysis
Background and purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side-effect of many commonly used cancer drugs, affecting up to 90% of patients treated with oxaliplatin. This systematic review and meta-analysis analysed randomised controlled trials (RCTs) to determine if any pharmacological agents or traditional medicines can prevent oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer (CRC) patients.Materials and methods: We searched PubMed, EMBASE and Web of Science for RCTs published before March 2025 that included patients with CRC who received oxaliplatin-based chemotherapy and had peripheral neuropathy quantified using Common Toxicity Criteria for Adverse Events (CTCAE). Meta-analysis was performed for agents tested in three or more RCTs with a minimum combined sample size of 100 patients.Results: 20 studies were included in the systematic review with a median sample size of 61 (range 14-2450). Meta-analysis was conducted for two treatments: first, agents with anti-oxidative stress properties and second, Ca2+/Mg2+ infusions. Anti-oxidative stress treatments were associated with a significant reduction of grade ≥2 OIPN at the end of treatment (OR:0.04, 95%CI:0.01-0.12; p2+/Mg2+ infusions. 35% of studies had potential high risk of bias and 45% of studies showed low risk of bias.Conclusions: Whilst the existing published RCTs included small numbers of patients, the meta-analysis indicates that anti-oxidative stress therapies can prevent severe OIPN developing at the end of treatment in CRC patients. A large, randomised, placebo-controlled trial assessing OIPN using CTCAE grades and patient-reported outcomes is warranted to confirm these findings.
- Open Access
Anti-oxidative stress therapies reduce chemotherapy-induced peripheral neuropathy in colorectal cancer patients treated with oxaliplatin: a systematic review and meta-analysis
Background and Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side-eaect of many commonly used cancer drugs, aaecting up to 90% of patients treated with oxaliplatin. This systematic review and meta-analysis aimed to analyse randomised controlled trials (RCTs) to determine if any pharmacological agents can prevent or reduce oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer (CRC) patients. Materials and Methods: We searched PubMed, EMBASE and Web of Science for RCTs published before March 2025 that included patients with CRC who received oxaliplatin-based chemotherapy and had peripheral neuropathy quantified using Common Toxicity Criteria for Adverse Events (CTCAE). Meta-analysis was performed for agents tested in three or more RCTs with a minimum combined sample size of 100 patients. Results: 20 studies were included with a median sample size of 61 (range 14-2450). Meta-analysis was used for two treatments. Anti-oxidative stress treatments were not associated with reduced incidence of grade ≥2 OIPN when assessed mid-treatment but were associated with a significant reduction of grade ≥2 OIPN at the end of treatment (OR:0.04, 95%CI:0.01-0.12; p2+ /Mg 2+ infusions. 35% of studies had potential high risk of bias and 45% of studies showed low risk of bias. Conclusions: Whilst the existing published RCTs included small numbers of patients, the meta-analysis indicates that anti-oxidative stress therapies reduce the end of treatment severe OIPN incidence in CRC patients. A large, randomised, placebo-controlled trial assessing OIPN using CTCAE grades and patient-reported outcomes is warranted to confirm these findings.
Open AccessAnti-oxidative stress therapies reduce chemotherapy-induced peripheral neuropathy in colorectal cancer patients treated with oxaliplatin: a systematic review and meta-analysis
Background and Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side-eaect of many commonly used cancer drugs, aaecting up to 90% of patients treated with oxaliplatin. This systematic review and meta-analysis aimed to analyse randomised controlled trials (RCTs) to determine if any pharmacological agents can prevent or reduce oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer (CRC) patients. Materials and Methods: We searched PubMed, EMBASE and Web of Science for RCTs published before March 2025 that included patients with CRC who received oxaliplatin-based chemotherapy and had peripheral neuropathy quantified using Common Toxicity Criteria for Adverse Events (CTCAE). Meta-analysis was performed for agents tested in three or more RCTs with a minimum combined sample size of 100 patients. Results: 20 studies were included with a median sample size of 61 (range 14-2450). Meta-analysis was used for two treatments. Anti-oxidative stress treatments were not associated with reduced incidence of grade ≥2 OIPN when assessed mid-treatment but were associated with a significant reduction of grade ≥2 OIPN at the end of treatment (OR:0.04, 95%CI:0.01-0.12; p2+ /Mg 2+ infusions. 35% of studies had potential high risk of bias and 45% of studies showed low risk of bias. Conclusions: Whilst the existing published RCTs included small numbers of patients, the meta-analysis indicates that anti-oxidative stress therapies reduce the end of treatment severe OIPN incidence in CRC patients. A large, randomised, placebo-controlled trial assessing OIPN using CTCAE grades and patient-reported outcomes is warranted to confirm these findings.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Methods 2: Overview of Biomarker analysis.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Methods 2: Overview of Biomarker analysis.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S8. The Variant Allele Frequency (VAF) of specific mutations changes during the course of the treatment. For instance, the VAF of ARID1a increases at treatment failure in patients 025 and 022 (both responders, Panel A). Furthermore, within the same patient, the VAF of different mutations changes coherently with the course of the treatment, as showed for patient 022 (B) and 002 (C), where the VAF increases at treatment discontinuation. Abbreviation: EOT, end of treatment.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S8. The Variant Allele Frequency (VAF) of specific mutations changes during the course of the treatment. For instance, the VAF of ARID1a increases at treatment failure in patients 025 and 022 (both responders, Panel A). Furthermore, within the same patient, the VAF of different mutations changes coherently with the course of the treatment, as showed for patient 022 (B) and 002 (C), where the VAF increases at treatment discontinuation. Abbreviation: EOT, end of treatment.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 4. List of antibodies used for mass cytometry
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 4. List of antibodies used for mass cytometry
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 1. Inclusion and exclusion criteria.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 1. Inclusion and exclusion criteria.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S5. Mean scores of global health status (GHS)/quality of life (QoL) and functioning domains on EORTC QLQ-C30 questionnaire at baseline and at the end of treatment.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S5. Mean scores of global health status (GHS)/quality of life (QoL) and functioning domains on EORTC QLQ-C30 questionnaire at baseline and at the end of treatment.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 8. Baseline characteristics of patients included in the circulating tumour DNA analysis.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 8. Baseline characteristics of patients included in the circulating tumour DNA analysis.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S2. Custom-developed bioinformatic variant calling pipeline to identify somatic SNVs and indels
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S2. Custom-developed bioinformatic variant calling pipeline to identify somatic SNVs and indels